Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
Do you recommend up-titrating the Metformin dose of patients with T2DM who are at goal A1c in order to decrease their risk of diabetes-related delirium?
https://doi.org/10.2337/dc24-1414
Related Questions
Do you avoid empagliflozin in patients with history of amputation?
What are the treatment options for severe recurrent hypoglycemia in a patient with malignant insulinoma?
What is the clinical importance of differentiating between impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) states?
Which patients would benefit most from teplizumab therapy to delay the onset of T1DM?
Which screening method for diabetes do you consider to be the most sensitive?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?
After what time frame off GLP-1 RA therapy should you restart at the lowest starting dose?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
Do you recommend the use of Korlym (Mifepristone) for patients with difficult to control diabetes and evidence of mild endogenous hypercortisolism of unknown source?
